NDC 53808-0990

TRIZIVIR

Abacavir Sulfate, Lamivudine, And Zidovudine

TRIZIVIR is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by State Of Florida Doh Central Pharmacy. The primary component is Abacavir Sulfate; Lamivudine; Zidovudine.

Product ID53808-0990_a6299f1c-1ddb-4da4-a38d-2cb34eca0c02
NDC53808-0990
Product TypeHuman Prescription Drug
Proprietary NameTRIZIVIR
Generic NameAbacavir Sulfate, Lamivudine, And Zidovudine
Dosage FormTablet, Film Coated
Route of AdministrationORAL
Marketing Start Date2013-02-01
Marketing CategoryNDA / NDA
Application NumberNDA021205
Labeler NameState of Florida DOH Central Pharmacy
Substance NameABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE
Active Ingredient Strength300 mg/1; mg/1; mg/1
Pharm ClassesHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2019-12-31

Packaging

NDC 53808-0990-1

30 TABLET, FILM COATED in 1 BLISTER PACK (53808-0990-1)
Marketing Start Date2013-02-01
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 53808-0990-1 [53808099001]

TRIZIVIR TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA021205
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2013-02-01
Inactivation Date2020-01-31

Drug Details

Active Ingredients

IngredientStrength
ABACAVIR SULFATE300 mg/1

OpenFDA Data

SPL SET ID:3354e50f-4dc5-413f-b5ae-87353ab8913d
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 285028
  • 307650
  • Pharmacological Class

    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]

    NDC Crossover Matching brand name "TRIZIVIR" or generic name "Abacavir Sulfate, Lamivudine, And Zidovudine"

    NDCBrand NameGeneric Name
    49702-217TRIZIVIRabacavir sulfate, lamivudine, and zidovudine
    53808-0990TRIZIVIRabacavir sulfate, lamivudine, and zidovudine

    Trademark Results [TRIZIVIR]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    TRIZIVIR
    TRIZIVIR
    78224812 2966217 Live/Registered
    VIIV HEALTHCARE COMPANY
    2003-03-12
    TRIZIVIR
    TRIZIVIR
    75726576 2379199 Dead/Cancelled
    VIIV HEALTHCARE COMPANY
    1999-06-10

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.